INTRODUCTION
A polymorphism in the promoter of the human CD14 gene (-260T>C) has been associated with Crohn's disease (CD) [1] [2] [3] and ulcerative colitis (UC) [3] [4] [5] , either alone or through interaction with polymorphisms in the CARD15 gene. 2, 6 However, other studies failed to detect association between CD14 and inflammatory bowel diseases (IBD); 7, 8 furthermore, the functional consequence of this polymorphism is not clearly defined. [9] [10] [11] Therefore, its role as a modifier of colitis has still to be elucidated. As we have previously identified Cd14 as a potential modifier of colitis susceptibility in IL10-deficient (Il10 -/-) mice this model system might be of great value to clarify the human situation. [12] [13] [14] In Il10 -/-mice, severity of IBD depends on the inbred strain carrying the IL10-mutation, indicating a major contribution from genetic background modifier genes. Previous linkage studies using an F2 and a first backcross population of highly susceptible C3H/HeJBir (C3/J)-
Il10
-/-and partially resistant C57BL/6J (B6)-Il10 -/-mice revealed 10 quantitative trait loci (QTL) that were associated with colitis susceptibility in these mice (Cdcs1-10, Cytokine-deficiency induced colitis susceptibility 1-10). 12, 13, 15 In the segregating populations used for QTLanalyses, i.e. under hybrid combinations, the susceptibel C3/J as well as the nominally resistant B6 parental genome contributed susceptibility alleles to the colitis subphenotypes.
This is considered as particularly relevant in understanding why colitis heritability in outbred human populations is so complex; 12,13 however, similar findings are often observed in QTLstudies. By combining mapping results with gene-expression analyses, we were able to identify eight candidate genes which may contribute to differential colitis susceptibility.
Among these genes, Cd14 was considered to be a major candidate because of very distinct expression differences in the C3 and B6 genetic backgrounds, 14 its function, and the association of the promoter-polymorphism with CD and UC. The mouse Cd14 gene is located within the interval of Cdcs6, a QTL at which the B6-and not the C3/J-allele contributed to colitis susceptibility.
CD14 is constitutively expressed as a membrane bound form (mCD14) on the surface of human monocytes, macrophages, and neutrophils. It is essential for LPS-signal transduction via TLR4 and also interacts with TLR2 for the detection of lipoproteins leading to NFκB activation. 16 A soluble form of CD14 (sCD14) is present in serum and shows ambiguous functions, as it promotes LPS-response in cells that do not express mCD14 17 but also reduces pro-inflammatory responses of mCD14 positive cells to LPS at high concentrations, 18, 19 probably by competitive binding. Data indicate that extra vascular sCD14 increases resistance against bacterial infections.
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A role of CD14 in IBD is not defined yet. So far, it was found to be expressed only at low levels in not inflamed intestine. 21, 22 However, we have identified considerable higher expression in the gut on mRNA and protein levels in the C3 than in the B6 genetic 3 background, even under germ-free conditions. We have furthermore excluded the possibility that the Tlr4 Lps-d allele of C3/J mice coding for a defective LPS-receptor causes expression differences. Besides expression differences in the intestine, we have observed that CD14 is differentially expressed on peritoneal macrophages of both strains after antigen stimulation.
14 As the role of CD14 is controversially discussed in human IBD, aim of this study was to elucidate the nature of differential intestinal Cd14 expression and whether it might contribute to IBD-susceptibility in mice. Because our genetic analyses showed that C3 mice carry IBD-resistance alleles at this QTL we hypothesized that CD14 protects against colitis. 
MATERIAL AND METHODS

Mice
Promoter analyses
Coding and promoter region (1067 bp upstream of the start codon) of the Cd14 gene were sequenced in B6 and C3/J mice after amplification using primer pairs 5'-CCA-CCG- CTG-TAA-AGG-AAA-GAA-AC-3'  and  5'-ACC-CAC-TGA-ACC-ATC-TTG-ACT-GC-3'   (annealing temperature: 56°C), 5'-ATT-TGA-ACG-GTG-GGA-AAT-TG-3' and 5'-CAG-AAG-CAA-CAG-CAA-CAA-GC-3', 5'-AAT-GAT-GAC-GAT-GAC-GAC-GA-3' and 5'-CAC-CGT-TCA-AAT-CCA-GCT-CT-3' (annealing temperature: 57°C) . Subsequently, Cd14-promoters of both strains were amplified by PCR using oligonucleotides 5'-ATC-TCG-AGA-ATG-ATG-ACG-ATG-ACG-AC-3' and 5'-CCA-GAT-CTA-TCT-GAG-AAG-TTG-CAG-GAA-CAA-C- 
Scoring of intestinal lesions in DSS-treated and Il10 -/-mice
Caeca and colons (including the rectum and anus) were removed, and processed for histology as described previously; 15 colons were prepared as a modified "Swiss role", caeca were cut into halves after fixation. Histopathologic lesions in DSS-treated mice were graded as follows: epithelial changes (crypts unchanged: 0, loss of basal 1/3: 1, basal 2/3: 2, complete: 3, loss of crypts plus ulceration: 4), cellular infiltration (none: 0, infiltrates in lamina propria: 1, in lamina propria plus oedema formation: 2, in lamina propria and submucosa: 3), area involved (none: 0, 10-30%: 1, 40-60%: 2, >60%: 3; for each parameter individually applied). This scheme was independently applied to caecum, proximal, medial and distal colon, yielding scores from 0-13 for each segment and 0-39 for total colon and 0-52 for colon plus caecum.
In Il10 -/-and Il10 -/-Cd14 -/-mice, colitis activity was monitored by histological grading of intestinal lesions according to the "TJL-score" described previously. 15 In short, four general criteria were evaluated in the above mentioned intestinal sections: 1) severity, 2) degree of hyperplasia, 3) degree of ulceration, if present, and 4) percentage of area involved. A range of 1-3 was used for each category. All 4 criteria were added and provided a total score for the section of large intestine evaluated, each ranging from 0 to 12. A total colon score (maximum possible = 36) was determined by adding the total score of all three sections of the colon. Furthermore, colitis activity was characterized by determination of red blood cell numbers and the hematocrit, and determination of cytokine secretion of isolated MLN cells after stimulation over 24 hours in anti-CD3 coated wells (2.5 μg/well; BD, Pharmingen, Hamburg, Germany) together with anti-CD28 (1 µg/ml; BD Pharmingen (Heidelberg, Germany) as described elsewhere.
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Immunofluorescence microscopy
Cryosections of colons were stained with biotin conjugated rat anti-mouse CD14- 
FACS-analyses
For isolation of intestinal cells colons were opened longitudinally and incubated in 
Detection of sCD14
6
A ready-to-use ELISA kit (CD14 soluble mouse detection set for ELISA application, Alexis, Lausen, Switzerland) was applied according to the manufacturer's protocol to detect sCD14 in serum or supernatants of colonic tissue or colonic crypt cell cultures. Supernatants were taken after 6 h of culture and frozen at -80°C until use.
Real-time RT PCR analysis
Real-time RT PCR analysis was conducted as described previously. 14 RNA was extracted using the Nucleospin ® RNAII kit (Macherey Nagel, Düren, Germany) and 1 µg was used for cDNA synthesis by Superscript II Reverse Transcriptase and oligo dT and random hexamer primers (Invitrogen, Carlsbad, CA, USA). Quantitative real-time RT PCR was performed in an ABI PRISM cycler (Applied Biosystems, Foster City, CA, USA) using a SYBR Green PCR kit from Stratagene (La Jolla, CA, USA) and specific primers. Relative mRNA levels were determined by using a standard curve and by further normalization to the house keeping Corporation, Karlsruhe, Germany]), using six wells per mouse strain. After one hour of incubation at 37°C and 5% CO 2 wells were washed by changing the medium twice. After 6 h, culture supernatants were transferred into microcentrifuge tubes and frozen at -80°C.
Crypt cell culture
Intestines were processed and cells were isolated as described for FACS-analyses (see previously) with slight modifications (the first incubation step took 10 min instead of 15 min, and composition of the second incubation medium contained 2 mM EDTA). Crypts were resuspended in Quantum 286 (PAA, Cölbe, Germany) with 100 µg/ml Gentamycin 
RESULTS
Modifying effect of CD14 in experimental colitis in vivo
A potential role of the CD14 protein in experimental IBD was investigated using Cd14 
DSS model
As C3/J mice (that were originally used for genetic analyses) carry the Tlr4 Lps-d allele rendering them LPS hyporesponsive, we considered this background as not suitable for analysing CD14 effects on colitis, as this protein interacts with TLR4 for LPS signaling.
Therefore, the LPS responsive C3/N substrain was used for this experiment, enabling us to focus on the effect of the CD14-deficiency without need to consider the defective TLR4 of C3/J mice as an additional variable. The C3/N substrain is often used as a control for the C3/J substrain; we have previously shown that C3/N mice also display high CD14 expression, which is therefore likely a characteristics of the C3-strain rather than a feature of certain C3-substrains or TLR4 status, respectively. Fig. 1A-F ). These differences were significant in the caecum, mid colon, total colon, and total intestine as determined by Mann-Whitney-U tests ( Fig. 2A) . After separating sexes, Kruskal-Wallis and the post-hoc Dunn test revealed more severe inflammation in the proximal colon of female C3/N-Cd14 -/-than in WT mice (p < 0.05).
Otherwise, no differences were detected between both sexes.
Histological data were supported by significant higher levels of IL1β in serum of C3/N-
Cd14
-/-mice compared to C3/N mice upon DSS-treatment (Fig. 2B) . Furthermore, extend of ulceration was measured (length of each ulcer in μm) in six randomly selected caeca of C3/N and C3/N-Cd14 -/-mice, and total area of ulceration in the caecum of each animal as well as mean extend of each ulcer determined. As shown in Figure 2C , Cd14 -/-mice displayed significantly more area of ulceration and larger mean ulcer sizes than WT mice. This might indicate that CD14-deficiency affects epithelial integrity.
In B6 mice, a significant difference in the severity of colitis was detected in the distal colon between Cd14 -/-and WT mice ( Fig. 2A) Fig. 1G-K; Fig. 3 ). Interestingly, Il10 -/-Cd14 -/-mice showed already a pronounced inflammation in the large intestine at 12 weeks of age, which we do not observe in B6-Il10 -/-controls ( Fig. 1G-K) . Degree of inflammation was identical in Il10 -/-mice carrying one or two copies of the Cd14 WT allele, therefore both were used as control groups ( (data not shown).
CD14 Expression
As in vivo analyses corroborated our previous study 14 and confirmed a protective effect of CD14 against experimental IBD, we subsequently searched for the source of differential CD14 expression in B6 and C3/J intestines.
CD14 in the gut: mCD14
Low expression of mCD14 was detected on cells isolated from colon and ileum of B6-
Il10
-/-and C3/J-Il10 -/-mice by FACS-analysis. mCD14-positive cells were not positive for any of the surface markers used to differentiate the cell-types; however, after depleting CD45 + cells and gating for size and granularity on intestinal epithelial cells (IEC), low expression of CD14 was detected on the surface of a minority of IECs (Fig. 4A) . Slightly more cells were CD14 + in the ileum than in the colon in C3/J-Il10 -/-and B6-Il10 -/-mice, but no strain differences were detected. Freshly isolated peritoneal macrophages (harvested by peritoneal lavage without subsequent culture) 14 served as a postive control (Fig. 4B ). Using immunofluorescence microscopy no mCD14 was detected in normal tissue of either B6-Il10
or C3/J-Il10 -/-mice but in inflamed tissue that served as a positive control. Therefore, mCD14
expression did not explain expression differences detected previously in not inflamed mucosa of both mouse strains.
CD14 in the gut: sCD14
Primary colonic tissue and crypt cell cultures were used to detect the soluble form of CD14. Supernatants of C3/J-Il10 -/-colonic tissue cultures contained significantly more soluble CD14 than those of B6-Il10 -/-cultures after 6 hours of incubation (Fig. 4C) . Furthermore, higher levels of sCD14 were detected in supernatants of primary crypt cells cultured from C3/J-Il10 -/-than from B6-Il10 -/-mice for 6 hours (Fig. 4C ). FACS analysis prior to culture ensured that less than 3% of the isolated cells were leukocytes. In concordance with the data presented above, neither G8.8 positive cells nor the few CD45 + cells showed surface expression of mCD14. These experiments strongly suggested that differential Cd14 expression between C3/J and B6 mice is due to differences in the release of sCD14 by IEC.
Extraintestinal CD14 expression
In the liver (which is the primary production site of serum CD14) no differences in Cd14 gene expression were detected by real-time RT PCR between C3/J-and B6-Il10
-/-mice; however, two-way ANOVA revealed significant more expression in livers of SPF than of germ-free mice (Fig. 4D) . The latter was also seen previously in the gut. In addition, serum levels of sCD14 were not significantly different between B6-and C3/J-mice under SPF conditions (B6 mice, mean: 41.2 ng/ml, SD: 15.4; C3/J mean: 32.7 ng/ml, SD: 16.3, t-test, p = 0.4). Therefore, different intestinal protein levels observed in this and our previous 14 study were unlikely due to carry over of serum CD14.
Relevance of sCD14 on TLR2 and TLR4 signalling in vitro
To investigate whether sCD14 concentrations detected in supernatants of colonic Whether the detected promoter polymorphisms affect gene expression was investigated in RAW264.7 cells transfected with a Cd14-promoter/luciferase reporter vector construct and stimulated with LPS (0.1 ng/ml). After 48 hours, a higher basal activity as well as higher activity upon LPS stimulation of the C3 promoter was observed (Fig. 6) , which is consistent with our expression data of the Cd14 gene.
DISCUSSION
The mouse Cd14 gene was identified as a potential candidate gene for modification of colitis susceptibility in experimental IBD by a combination of QTL mapping and microarray analyses in previous studies. 14 Cd14 is located within the interval of the B6-derived QTL Cdcs6 on chromosome 18, the human homologue within a susceptibility region for human IBD on chromosome 5q (IBD5). Cd14 was considered to be a good candidate gene because of expression differences between B6-(low Cd14 expression, presumably conferring susceptibility) and C3/J-Il10 -/-mice (high Cd14 expression, presumably conferring resistance)
as well as between the respective WT strains in microarray analyses, real-time RT PCR, and at protein level in the intestine. Furthermore, CD14 was found to be differentially expressed on peritoneal macrophages after antigen stimulation. This study was designed to investigate if Cd14 expression in the gut modifies IBD susceptibility.
Although the role of Cd14 in normal gut was undetermined, there was evidence that murine colonic epithelial cells do express mCD14, 21 and this protein was even detected on a minority of resident macrophages in normal human intestine. 22 Human epithelial cell lines were shown to produce sCD14. 27 Under inflammatory conditions, CD14 expression increases in the gut in humans 28 and mice 21 . We have observed only weak expression of mCD14 in normal colon and ileum mucosa by FACS, exclusively on epithelial cells, but no strain 12 difference was detectable. By immunohistochemistry, mCD14 positive cells were detected only in inflamed intestinal tissue. As this was contradictory to our previous results, we investigated if the soluble form of this protein is present in the gut, which was not done to our best knowledge before. Therefore, colonic tissue and crypt cells of B6 and C3/J mice were cultured and sCD14 was measured in the supernatant by ELISA. Significantly higher levels of sCD14 were secreted by colonic tissue and isolated crypt cells of C3/J mice, explaining our previous observations. Serum levels of sCD14 and Cd14 expression in the liver (the main production site of serum sCD14) did not differ between B6 and C3/J mice excluding the possibility that a carry-over of serum sCD14 caused different sCD14 concentrations measured in culture supernatant.
In humans, a -260C>T (also known as -159C>T) polymorphism in the promoter of the CD14 gene was shown to be associated with Crohn's disease [1] [2] [3] and ulcerative colitis [3] [4] [5] , or
showed interaction with polymorphisms in the CARD15 gene 2, 6 ; however, in other studies an association to IBD was not detected, 7,29 underlining genetic heterogeneity in IBD patients.
LeVan and colleagues showed that the CD14/-159 T allele decrease binding of the repressor SP2; 30 however, the effect of this polymorphism is still not fully elucidated. We have detected spontaneously due to the lack of NFκB activation in epithelial cells. 34 However, under proinflammatory conditions, detrimental effects have been observed by TLR activation. This contrasting effects were investigated in detail for bacterial DNA motifs. 35, 36 Furthermore, germ-free mice develop more severe colitis upon DSS-treatment than conventional mice, 37, 38 while therapeutical treatment with antibiotics was protective in the same colitis model. This observation corroborates the hypothesis that expression differences contribute to strain specific susceptibilities to experimental IBD and support the concept that human CD14
promoter polymorphisms contribute to disease development. Most likely, CD14 mediates its effect through innate immune mechanisms, possibly by enhancing intestinal barrier functions.
Thereby, this study underlines the importance of innate mechanisms in aetiology and development of therapeutic strategies in IBD. The C3/J promoter showed significant more basal acitvity and more activity upon LPS stimulation than the B6 promoter (p<0.0001, determined by ANOVA; n = 4). Activity of the control vector pGL4.10 (pGL) is shown.
